Skip to content
UL-straight-talk-pill-web-12

Give them independence from med dependence

Half of men surveyed report dissatisfaction with BPH medications.ι  The UroLift™ System offers rapid symptom relief, significant improvement in quality of life, and may enable patients to discontinue BPH meds.ιι, ιιι

Learn More

Accelerate Your BPH Patients’ Path to Better Living

Graphic showing the path from Initial BPH symptoms to BPH symptom relief

For decades, treating BPH has meant making a hard choice between medications, which may have bothersome side effects,8 or surgical treatment, with risk of sexual dysfunction.10

Now you can change a patient’s journey with confidence. The UroLift™ System can help men get off BPH medications and avoid major surgery.2 This straightforward procedure provides rapid symptom relief and recovery3,4 and preserves sexual function.*2

AUA BPH Guideline Recognize the Need for Earlier Intervention

“Since many men discontinue medical therapy, yet proportionately few seek surgery, there is a large clinical need for an effective treatment that is less invasive than surgery. With this treatment class, perhaps a significant portion of men with BOO [bladder outlet obstruction] who have stopped medical therapy can be treated prior to impending bladder dysfunction.5”

The UroLift™ System is part of the standard of care for BPH treatment.5

Bladder Disease Progression from a healthy bladder to a permanently damaged bladder

What is UroLift™?

The UroLift™ System is the only leading enlarged prostate procedure that does not require heating, cutting, removal, or destruction of prostate tissue.3,10

Treatment with the UroLift™ System can be performed as a same-day outpatient procedure, including the office setting, under local anesthesia.4 It does not preclude future BPH treatments, should they be necessary.2

Icon of a shield

Safety

Risk profile better than reported for surgical procedures such as TURP3,8,9

Icon of a crosshair

Efficacy

Rapid symptom relief and recovery3,4  with no new, sustained erectile or ejaculatory dysfunction*10,12

Icon of a link

Proven Durability

Proven to achieve sustained improvements in IPSS, QoL, and Qmax through 5 years2

Zero Day Global

The UroLift™ System is covered by Medicare, national, and commercial plans, when medical criteria are met. It is the only minimally invasive BPH procedure that has a zero day global.

Faster Recovery. Fewer Risks. Proven Outcomes.2,4,8,10

UroLift celebrating more than 500,000 men treated for BPH
Icon of a bar chart

Patient Experience
Lowest rate of complications at one year when compared to both minimally invasive and invasive procedures.**14

89%

of obstructive median lobe patients would recommend the procedure at 1 month11

Simplified UroLift logo

Durable Results
Improvements in symptoms, urinary flow, and quality of life sustained through 5 years2 with a retreatment rate of 13.5% at 5 years.2,3

50%

improvement in quality of life sustained over a 5 year study2

Icon of two people in bed

Preservation of Sexual Function
The only leading BPH procedure shown not to cause new and lasting sexual dysfunction.*10,12

0%

ejaculatory and erectile dysfunction*2

The Right Solution for Many BPH Patients

The UroLift™ System provides consistent outcomes to a broad range of BPH patients.13

Prostate Indications for the UroLift™ System✝
Minimum prostate volume None
Maximum prostate volume 100 cc
Obstructive median lobe Yes

The UroLift™ System Real World Retrospective Registry demonstrates that patients outside of the norm seen in clinical trials can be treated safely and effectively.13

  • Younger patients
  • Patients in retention
  • Prostates <30cc
  • History of prostate cancer treatment
  • Diabetic patients

500,000

BPH patients have been treated with the UroLift™ System15

Download Brochure

What are doctors saying?

Physician talking to a patient
“The UroLift clinical publication record is flawless… The outcomes from the numerous studies are consistent—demonstrating rapid relief within two weeks and sustained improvement in symptoms, quality of life and urinary flow.”
Claus Roehrborn, MD+
“The procedure has allowed me to regain my quality of life. I have no urgency, no frequency and I’m thoroughly satisfied with the results.”
Stephen Richardson, MD (patient)

References

  • 1. U.S. 2022 estimates based on US Market Model 2022-24 (5-17-22 FINAL), which is in part based on Symphony Health PatientSource® 2018-21, as is and with no representations/ warranties, including accuracy or completeness.

  • 2. Roehrborn, Can J Urol 2017 

  • 3. Roehrborn, J Urology 2013  

  • 4. Shore, Can J Urol 2014 

  • 5. AUA Guidelines 2021 

  • 6. Flanigan, J Urol 1998

  • 7. Tubaro, Drugs Aging 2003

  • 8. Sonksen, Eur Urol 2015

  • 9. AUA BPH Guidelines 2003

  • 10. AUA BPH Guidelines 2003, 2020

  • 11. Rukstalis, Prostate Cancer Prostatic Dis 2018

  • 12. McVary, Urology 2019

  • 13. Eure, J Endourol 2019

  • 14. Kaplan, Prostate Cancer Prostatic Dis 2023

  • 15. Management estimate based on product sales as of June 2024. Data on file Teleflex Interventional Urology

  • † Food and Drug Administration (FDA) patient criteria for the UroLift™ System

  • *No instances of new, sustained erectile or ejaculatory dysfunction in the L.I.F.T. pivotal study

  • **Procedural complications were defined as complications requiring a return procedure in the outpatient setting ≥1d post-procedure

  • + Paid consultant of Teleflex Interventional Urology

MAC12000-00 Rev A